Gene:
IL12B
interleukin 12B
PharmGKB contains no prescribing info for this . Contact us to report known genotype-based dosing guidelines, or if you are interested in developing guidelines.
1. Annotation of FDA Label for ustekinumab and IL12A,IL12B,IL23A
Summary
The FDA-approved drug label for ustekinumab (STELARA) states that serious infections from mycobacteria, salmonella and BCG vaccinations have been reported in patients who are genetically deficient in IL-12/IL-23, and that diagnostic tests for these infections should be considered as dictated by clinical circumstances.
Annotation
Ustekinumab (STELARA) is a human interleukin-12 and -23 antagonist indicated for the treatment of adult patients with plaque psoriasis, psoriatic arthritis or Crohn's disease.
Excerpt from the ustekinumab (STELARA) drug label:
Theoretical Risk for Vulnerability to Particular Infections...Individuals genetically deficient in IL-12/IL-23 are particularly vulnerable to disseminated infections from mycobacteria (including nontuberculous, environmental mycobacteria), salmonella (including nontyphi strains), and Bacillus Calmette-Guerin (BCG) vaccinations. Serious infections and fatal outcomes have been reported in such patients. It is not known whether patients with pharmacologic blockade of IL-12/IL-23 from treatment with STELARA may be susceptible to these types of infections. Appropriate diagnostic testing should be considered, e.g., tissue culture, stool culture, as dictated by clinical circumstances.
For the complete drug label text with sections containing pharmacogenetic information highlighted, see the ustekinumab drug label.
*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.
Genes and/or phenotypes found in this label
PharmGKB contains no Clinical Variants that meet the highest level of criteria.
To see more Clinical Variants with lower levels of criteria, click the button at the bottom of the table.
Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.
The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.
The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.
The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page on the appropriate tab.
Links in the "Drugs" column lead to PharmGKB Drug Pages.
List of all variant annotations for IL12B
|
Variant?
(147) |
Alternate Names ? | Chemicals ? |
Alleles
?
(+ chr strand) |
Function ? |
Amino Acid?
Translation |
|
|---|---|---|---|---|---|---|
| rs2546890 |
A > G
|
SNP | ||||
| rs3212217 |
C > G
|
SNP | ||||
| rs3212227 |
T > G
|
SNP | ||||
| rs3213094 |
C > T
|
SNP | ||||
| rs6894567 |
A > G
|
SNP |
Overview
| Alternate Names: | IL12, subunit p40; NKSF2; cytotoxic lymphocyte maturation factor 2, p40; interleukin 12, p40; interleukin 12B (natural killer cell stimulatory factor 2, cytotoxic lymphocyte maturation factor 2, p40); interleukin-12 beta chain; natural killer cell stimulatory factor, 40 kD subunit; natural killer cell stimulatory factor-2 |
|---|---|
| Alternate Symbols: | CLMF; CLMF2; IL-12B; NKSF |
| PharmGKB Accession Id: | PA29785 |
Details
| Cytogenetic Location: | chr5 : q31.1 - q33.1 |
|---|---|
| GP mRNA Boundary†: | chr5 : 158741791 - 158757481 |
| GP Gene Boundary†: | chr5 : 158738791 - 158767481 |
| Strand: | minus |
Visualization
UCSC has a Genome Browser that you can use to view PharmGKB annotations for this gene in context with many other sources of information.
View on UCSC BrowserCurated Information ?
| Evidence | Drug |
|---|---|
| adalimumab | |
| etanercept | |
| methotrexate | |
| pravastatin | |
| ustekinumab |
| Evidence | Drug Class |
|---|---|
| Tumor necrosis factor alpha (TNF-alpha) inhibitors |
Curated Information ?
Publications related to IL12B: 12
LinkOuts
- UniProtKB:
- IL12B_HUMAN (P29460)
- Ensembl:
- ENSG00000113302
- GenAtlas:
- IL12B
- GeneCard:
- IL12B
- MutDB:
- IL12B
- ALFRED:
- LO014402L